*Letter of intent is due at least two weeks prior to deadline
AFTD RFP: Research investigating the pathelogical mechanisms underlying Frontotemporal Dementia (FTD) is advancing, creating new targets for drug discovery. As potential therapies move forward, the need for biomarkers for early diagnosis, to distinguish FTD subtypes, and to monitor disease progression is also critical. The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Dementia (AFTD) seek to accelerate and support innovative drug discovery programs and biomarker development for FTD through this RFP. See full RFP.
DEADLINES for all other 2015 RFPs:
*Letter of intent is due at least two weeks prior to each deadline for consideration in that funding cycle
ApoE RFP: The Alzheimer's Drug Discovery Foundation (ADDF) and the Robert A. and Renée E. Belfer Family Foundation established The ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. See full RFP.
PRECLINICAL DRUG DISCOVERY RFP: The Alzheimer's Drug Discovery Foundation (ADDF) seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, other dementias and cognitive aging. See full RFP.
PACT RFP: The ADDF has created the Program to Accelerate Clinical Trials (PACT) to increase the number of innovative drugs tested in humans at the crucial proof of concept stage for Alzheimer’s disease. This program will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer’s. See full RFP.
ADDF/NIH RFP: The ADDF will consider financial assistance for relevant NIH grant applications that were scored but not funded in response to certain NIH funding opportunities. Application deadline is rolling. See full RFP.